Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

NCT06601296 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma ( mRCC)
OligoProgressive Metastatic Disease

Interventions

DRUG: IMSA101

Sponsor

University of Texas Southwestern Medical Center